M&A Corner
Prolucent Secures $4M for Healthcare Workforce Optimization30 Oct 2023
Dallas-based Prolucent, specializing in healthcare workforce optimization, has secured $4M from A1 Health Ventures. Joe Greskoviak, ex-CEO of Press Ganey,... Continue Reading
|
Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment30 Oct 2023
Pangea Biomed and FibroFighters have partnered to combat fibrolamellar carcinoma (FLC), a rare liver cancer primarily affecting young individuals without... Continue Reading
|
Nucleus RadioPharma Secures $56M to Expand Radiopharmaceutical Treatments for Cancer Patients30 Oct 2023
Nucleus RadioPharma, pioneering in integrated development, manufacturing, and radiopharmaceutical supply, has raised an oversubscribed $56 million in Series A funding.... Continue Reading
|
EU Antitrust Regulators Clear Pfizer’s $43B Acquisition of Seagen21 Oct 2023
The European Commission has given its unconditional approval for Pfizer’s $43 billion acquisition of Seagen, a company specializing in antibody-drug... Continue Reading
|
Alaya.bio Acquires Key Assets From Ixaka France, Accelerating the Progress of Its Novel In Vivo CAR-T Immunotherapy Platform21 Oct 2023
Alaya.bio, a biotech company specializing in in vivo gene delivery, has acquired all assets of Ixaka France, a preclinical-stage immunotherapy... Continue Reading
|
Thomas Scientific Broadens Portfolio and Sales Expertise With the Acquisition of Arrowhead Forensics21 Oct 2023
Thomas Scientific, North America’s largest distributor of scientific products, successfully acquired Arrowhead Forensics, a forensics product provider based in Lenexa,... Continue Reading
|
Ayala Pharmaceuticals Announces Closing of Merger with Biosight21 Oct 2023
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, has successfully completed its merger with Biosight, Ltd. The merged entity... Continue Reading
|
Basilea Announces Acquisition of Novel Clinical-Stage Antifungal for Treatment of Aspergillus Mold Infections21 Oct 2023
Basilea Pharmaceutica Ltd (SIX: BSLN) has entered an asset purchase agreement with Gravitas Therapeutics Inc. for GR-2397, now known as... Continue Reading
|
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million21 Oct 2023
Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical biotech firm focused on revolutionary treatments for immune diseases, has finalized its... Continue Reading
|
Advanced Biologics Elevates Biologic Innovations Through Merger with Isto Biologics.21 Oct 2023
Biologica Technologies, a California-based innovator in biologic solutions, has successfully merged with Isto Biologics, a global leader in regenerative therapies.... Continue Reading
|